[Critical observations on therapy of malignancy with the cytostatic Bayer A 139 in otorhinolaryngological therapeutics].
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001388:Aziridines; D016227:Benzoquinones; D053138:Cyclohexenes; D004428:Ear Neoplasms; D009296:Nasal Cavity; D009369:Neoplasms; D010255:Paranasal Sinus Neoplasms; D010614:Pharynx
D000970:Antineoplastic Agents; D001388:Aziridines; D016227:Benzoquinones; D053138:Cyclohexenes; C006052:2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone
CYTOTOXIC DRUGS/therapeutic use; EAR/neoplasms; NASAL CAVITY/neoplasms; THROAT/neoplasms
Kritische Bemerkungen zur Malignomtherapie mit dem Cytostaticum Bayer A 139 in der Hals-Nasen-Ohrenheilkunde.